Published in Therap Adv Gastroenterol on March 01, 2012
Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43
Direct anti-HCV agents. Acta Pharm Sin B (2015) 0.94
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients. Antimicrob Agents Chemother (2014) 0.82
Management of anorectal symptoms associated with telaprevir. Gastroenterol Hepatol (N Y) (2012) 0.75
Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market. Croat Med J (2016) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology (2010) 4.19
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology (2011) 2.95
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis (2008) 2.69
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother (2006) 2.42
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
Natural history of hepatitis C. J Hepatol (1999) 2.31
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology (2011) 2.24
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother (2006) 1.69
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57
Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther (2010) 1.51
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol (2008) 1.49
Hepatitis B and hepatitis C in 2009. Liver Int (2009) 1.47
Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat (2011) 1.25
New HCV therapies on the horizon. Clin Microbiol Infect (2011) 1.23
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol (2010) 1.17
Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther (2010) 0.88
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol (2005) 2.37
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology (2012) 1.94
Pharmacology and therapeutic potential of interferons. Pharmacol Ther (2012) 1.76
Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med (2004) 1.71
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol (2005) 1.59
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology (2015) 1.42
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology (2013) 1.41
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol (2012) 1.32
Type I interferons and the innate immune response--more than just antiviral cytokines. Mol Immunol (2005) 1.26
Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun (2006) 1.21
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health (2011) 1.20
Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. Immunology (2005) 1.04
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut (2011) 1.00
Global hepatitis, migration and its impact on Western healthcare. Gut (2010) 0.94
Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. Hepat Mon (2013) 0.92
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol (2011) 0.91
Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ (2012) 0.90
Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol (2006) 0.90
Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Ann Surg (2016) 0.88
Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proc Natl Acad Sci U S A (2013) 0.86
HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Gut (2012) 0.86
An orally available, small-molecule interferon inhibits viral replication. Sci Rep (2012) 0.84
Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. J Gastroenterol Hepatol (2011) 0.84
Cryptosporidium parvum infection rapidly induces a protective innate immune response involving type I interferon. J Infect Dis (2009) 0.83
Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis (2008) 0.81
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol (2011) 0.81
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol (2004) 0.80
Managing diabetes in patients with chronic liver disease. Postgrad Med (2012) 0.80
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A (2007) 0.80
Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta. J Interferon Cytokine Res (2003) 0.79
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS (2014) 0.79
Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction (2008) 0.78
Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med (2016) 0.78
The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - results from a community based survey and laboratory surveillance. Travel Med Infect Dis (2013) 0.78
Diagnosis and treatment of hepatitis C. J R Soc Med (2004) 0.78
IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration. J Interferon Cytokine Res (2007) 0.78
Different activities of type I interferons on hepatitis B virus core promoter regulated transcription. Cytokine (2002) 0.78
High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli. Protein Expr Purif (2003) 0.77
Diagnosis and treatment of chronic hepatitis B. J R Soc Med (2004) 0.77
Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis". J Hepatol (2013) 0.75
Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. Clin Med (2011) 0.75
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver Int (2014) 0.75
The Journal Of Viral Hepatitis 2016. J Viral Hepat (2016) 0.75
Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Eur J Gastroenterol Hepatol (2012) 0.75
Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. Eur J Gastroenterol Hepatol (2016) 0.75